Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Geographic Atrophy GA Companies

ID: MRFR/HC/9297-HCR
120 Pages
Vikita Thakur
Last Updated: February 16, 2025
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition that can lead to vision loss. Geographic atrophy specifically involves the atrophy or degeneration of the central part of the retina known as the macula.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Geographic Atrophy GA Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.8%
2024 Market Size$ 1.45 Billion
2025 Market Size$ 1.56 Billion
2035 Market Size$ 2.99 Billion
Key Players
Novartis
Regeneron Pharmaceuticals
Roche
Bayer
Alcon
Pfizer
Trends
  • Rising Prevalence of Age-Related Macular Degeneration
  • Advancements in Diagnostic Technologies
  • Growing Public Awareness Initiatives
Opportunities
  • Increasing Aging Population
  • Rising Healthcare Expenditure
  • Government Initiatives and Policies
Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Geographic Atrophy GA Market

Geographic Atrophy Key Companies
 
Latest Geographic Atrophy Companies Update:

Second FDA Approval for GA Treatment: In August 2023, Iveric Bio received FDA approval for Izervay (avacincaptad pegol), the second ever-approved treatment for GA after Syfovre (pegcetacoplan injection). This offers increased options and hope for patients.

Focus on Novel Treatment Approaches: Companies like Apellis Pharmaceuticals and Gyroscope Therapeutics are researching and developing gene therapy and stem cell-based therapies for GA, potentially offering long-term solutions.

Clinical Trial Momentum: Several promising Phase 3 clinical trials are underway for potential GA treatments, including NGM Bio's NGM621 and Alkeus Pharmaceuticals' Gildeuretinol.

Diagnostic Advancements: New imaging technologies like swept-source Optical Coherence Tomography (OCT) are improving early detection and monitoring of GA progression, leading to timely treatment initiation.

List of Geographic Atrophy Key companies in the market
  • Apellis Pharmaceuticals, Inc. (US)
  • Iveric Bio (US)
  • Alkeus Pharmaceuticals, Inc. (US)
  • Hemera Biosciences LLC (US)
  • Allegro Ophthalmics, LLC (US)
  • Stealth BioTherapeutics (Cayman Islands)
  • Gyroscope Therapeutics Limited (UK)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Genentech, Inc. (US)
  • Gensight Biologics SA (France)

Related Reports

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035